Also, it is reasonable to conclude that combinatorial targeting of ERBB2 and RANKL could be a more effective approach, which would overcome RANKL effect in suppressing anti-tumor action of anti-ERBB2 agents. The gene discussed is TNFSF11; the disease is neoplasm.